20/20 OptimEyes Technologies

20/20 OptimEyes Technologies has developed a mucoadhesive drug delivery platform technology that allows for improved solubility of APIs and extended release. Initially validated as an eye drop, we have a successful lead pre-clinical program in glaucoma and are exploring new indications in other mucosal areas.

Contact: info@2020optimeyes.ca